Adaptive Biotechnologies enters its Thursday earnings release with a striking internal contradiction: the stock has rallied more than 38% year-to-date, yet the company's own founder has been selling aggressively all month.
The insider selling is the standout story this week. Harlan Robins, the company's Founder and Chief Scientific Officer, has sold over 878,000 shares across multiple transactions since July 2, raising roughly $18.5 million at prices between $21.72 and $22.45. That comes on top of $3.4 million in sales from HR Director Francis Lo and a smaller clip from the Chief Commercial Officer. In aggregate, the 90-day insider net comes to approximately $32.6 million in stock sold. None of these are micro transactions — the Robins disposals alone span multiple days and price points, suggesting a deliberate, planned reduction rather than a one-off. The stock now trades at $22.52, sitting almost exactly where insiders have been booking out.
Options positioning turned sharply more defensive on Tuesday. The put/call ratio jumped to 0.171 — more than 3.6 standard deviations above its 20-day average of 0.026. That is not a rounding error: the prior 20 sessions had PCR readings almost uniformly below 0.02, making Tuesday's spike look like a sudden and concentrated demand for downside protection ahead of the print. The 52-week high on the PCR is 0.678, so this is not yet at maximum alarm — but the move from near-zero to the highest reading since late June in a single session, right before results, is notable. The borrow market, by contrast, remains completely unbothered. Availability is running at roughly 580%, meaning shares available to lend vastly outnumber those already borrowed. Cost to borrow is just 0.48%, near its 30-day lows. Short interest at 7.4% of the free float is meaningful but has been drifting lower all week, down about 2% on the week. The positioning story here is not a short squeeze setup — it's options traders hedging into a binary event while lenders sit comfortably on the sidelines.
The Street is cautiously constructive but not exactly rushing to raise targets. The consensus leans toward Buy, with Morgan Stanley the notable holdout at Equal-Weight. Morgan Stanley raised its target to $20 on July 9 — still below where the stock is trading today at $22.52. Guggenheim pushed its Buy target up to $22 in late June, and BTIG has held firm at $22 with a Buy. The mean target across the analyst group is approximately $22.29, which is essentially in line with the current price. The stock has, in other words, run past the Street's collective view. Factor scores underline the ambivalence: EPS momentum ranks in the bottom 15th percentile on both the 30-day and 90-day basis, and the short score of 52.7 is mid-range. The ORTEX short score has eased slightly from a local peak of 55.3 last Thursday, a modest reduction in bearish signal heading into the event. The bull case rests on continued clonoSEQ MRD test adoption and the strategic separation of that business; bears point to the premium valuation — the stock trades at roughly 172x EV/EBITDA — and execution risk in a competitive specialty lab market.
Two prior post-earnings reactions offer asymmetric context. After the June 5 report the stock fell 7.6% the next day and ended the five-day window down 2.7%. After the May 5 report it was flat on the day but down 6% over the following week. Neither print was rewarded. Positive surprises, if delivered, have not translated into sustained gains in recent quarters — a pattern worth holding in mind when reading the PCR spike.
What to watch Thursday is whether reported clonoSEQ test volumes and the revised revenue outlook come in above the raised guidance that has already driven the year-to-date rally — because with the stock sitting at analyst targets and the founder selling throughout the run-up, the bar for a positive price reaction looks higher than the consensus framing suggests.
See the live data behind this article on ORTEX.
Open ADPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
